Related Experiment Video
Updated: May 22, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?
1Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. mp@marilynpike.com
Current Rheumatology Reports
|May 15, 2012
Summary
Developing treatments for systemic lupus erythematosus (SLE) is challenging due to its varied symptoms. New methods are being used to collect and analyze clinical data for SLE drug development.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Significant advances in basic science and pharmacology have yielded treatments for inflammatory diseases like rheumatoid arthritis and multiple sclerosis.
- Developing new therapies for systemic lupus erythematosus (SLE) has lagged due to challenges in consistently measuring therapeutic effects owing to its diverse clinical manifestations.
Purpose of the Study:
- To describe approaches facilitating the collection, review, and analysis of clinical measures for SLE drug development.
- To address the difficulties in uniformly applying complex composite endpoints across multiple clinical sites in global SLE studies.
Main Methods:
- Utilizing independent central adjudication committees for the review and analysis of clinical data.
- Implementing standardized approaches for collecting and analyzing diverse clinical measures in SLE trials.
Main Results:
- Central adjudication facilitates consistent review of complex clinical data.
- Standardized data collection and analysis improve the reliability of therapeutic effect measurements in SLE.
Conclusions:
- Central adjudication committees are crucial for overcoming challenges in SLE clinical trial data management.
- These approaches are vital for advancing the development of new treatments for systemic lupus erythematosus (SLE).
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...